Navigation Links
Omeros Announces First Patients Treated in Phase 3 Clinical Program Evaluating OMS302
Date:10/11/2011

ll-known safety and pharmacologic profiles. FDA-approved drugs containing each of these APIs have been used in ophthalmological clinical practice for more than 15 years, and both APIs are contained in generic, FDA-approved drugs.

In a 221-subject Phase 2b clinical trial that evaluated OMS302 in patients undergoing cataract surgery, OMS302 demonstrated clinically meaningful and statistically significant benefits in both prespecified co-primary endpoints – maintenance of intraoperative mydriasis and reduction of pain in the early postoperative period. OMS302 also reduced the frequency of complaints of moderate and severe pain.

About Omeros Corporation

Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has four ongoing clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, coagulopathies and central nervous system disorders.

Forward-looking Statements

This press release contains forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, which are subject to the "safe harbor" created by those sections. These statements include, but are not limited to, statements regarding the Company's expectations that data from the first Phase 3 trial of OMS302 will be available during the first quarter of 20
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
2. Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery
3. Omeros Announces Patient Enrollment in Phase 1/Phase 2 Study of OMS302
4. Omeros and The Parkinsons Institute and Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders
5. Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program
6. Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share
7. Omeros Announces National Institute on Drug Abuses Support for Phase 2 Clinical Study in Addiction Program
8. Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19
9. Daniel K. Spiegelman Elected to Board of Directors of Omeros
10. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
11. Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)...   LabStyle Innovations Corp . (OTCQB:DRIO), developer of ... appointment of Professor Richard B. Stone ... Directors. Prof. Stone brings over forty-five ... as an entrepreneur, venture capitalist public, company officer ... He currently serves on the board of directors ...
(Date:1/15/2014)... Jan. 15, 2014 Most osteoporosis patients want a ... recent online survey* sponsored by Mission Pharmacal Company. The ... Osteoporosis Foundation online support community, revealed that 74 percent ... comes in a form other than a pill or ...
(Date:1/15/2014)... LAWRENCEVILLE, N.J. , Jan. 15, 2014  Celsion Corporation (the ... it has received commitments from institutional investors to purchase ... common stock in an at-the-market registered direct offering, led ... Company entered into definitive purchase agreements with these investors ...
Breaking Medicine Technology:LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3
... Reportlinker.com announces that a new market research ... Advanced Drug Delivery Markets (Liposomes, Polymers and ... Drug delivery is evolving at a ... discovered frequently. Advanced drug delivery deals with developing ...
... Jan. 11, 2011 Reportlinker.com announces that a ... catalogue: France Pharmaceutical Market Overview ... http://www.reportlinker.com/p0360215/France-Pharmaceutical-Market-Overview-–--Austerity-measures-will-impact-pharmaceutical-market-growth.html ... pharma market in France was valued at $38.8bn ...
Cached Medicine Technology:Reportlinker Adds Advanced Drug Delivery Markets (Liposomes, Polymers and Monoclonal Antibodies) 2Reportlinker Adds Advanced Drug Delivery Markets (Liposomes, Polymers and Monoclonal Antibodies) 3Reportlinker Adds France Pharmaceutical Market Overview - Austerity measures will impact pharmaceutical market growth 2
(Date:7/11/2014)... 2014 Alliance for Cancer Gene ... dedicated exclusively to cell and gene therapies for ... joined the organization as Senior Development Officer. , ... experience securing gifts and addressing influential donors. Prior ... Director for NewYork Presbyterian Hospital/Columbia University Medical Center, ...
(Date:7/11/2014)... As reported by the New York Times ... number of severe adverse events such as renal failure, ... from the highly-promoted and costly immune-system drug, Acthar, have ... , a regulatory filing revealed that the total number ... 14% of prescriptions, up from 9.1% in 2011. Specifically, ...
(Date:7/11/2014)... surgery to repair damage to the anterior cruciate ligament (ACL) ... -- could increase a young athlete,s risk for further injuries, ... patients, aged 8 to 16, who had ACL reconstruction surgery. ... after their injury, 37 had surgery six to 12 weeks ... after their injury. The youngsters who had surgery later ...
(Date:7/11/2014)... 2014 Riverside Health System became the first ... Virginia in late 2012 and now, in partnership with Williamsburg ... throughout the Williamsburg and Newport News region. , Also known ... benefits to independent older adults who wish to remain in ... net of continuing care services as well as control over ...
(Date:7/11/2014)... unravel mechanisms that guide function and differentiation of blood ... including our immune system. The study of human blood ... found in the bone marrow in specialized "niches" that ... group of scientists from Dresden led by stem cell ... to generate a mouse model that supports the transplantation ...
Breaking Medicine News(10 mins):Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 3Health News:Acthar’s Deadly Adverse Events Revealed 2Health News:Acthar’s Deadly Adverse Events Revealed 3Health News:Delaying Kid's Knee Surgery Could Be a Bad Play, Study Finds 2Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 2Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 3Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 4Health News:Opening-up the stem cell niche 2
... and ISMANING, Germany, Oct. 17 /PRNewswire-FirstCall/,-- XIRING ... security solutions,for remote transactions, and SCM Microsystems ... of solutions that open the Digital,World, today ... eHealth,smart card terminals for the new generation ...
... today filed an amicus brief on behalf of ten ... RU-486., AUL President Dr. Charmaine Yoest stated, "RU-486 ... women,s lives. We must put a stop to,abortionists, dangerous, ... in the right direction, and as we argue in ...
... into any grocery store,and there,s likely to be ... struggle with mindless eating have already begun to ... people find that Halloween spurs,a particularly tough time ... coming, it,only becomes more challenging. Dieters, mindless eaters, ...
... SPRINGFIELD, Mass., Oct. 16 With a combination ... become its hallmark, Massachusetts Mutual Life Insurance Company,(MassMutual) ... to the cause,of Breast Cancer Awareness Month., ... contribute tens of thousands,of dollars to cancer research, ...
... Alert Urges HR/Leadership Development to Implement Post-Crash Development Programs with ... ... Gainesville, FL (PRWEB) October 16, 2008 -- ... and how human resources and leadership development can quickly ...
... researcher, clinical nutritionist and women,s health practitioner, has ... Revitalizer, designed to bring back thicker, fuller hair ... Nails Revitalizer is available exclusively through Doctors, Preferred, ... one of the largest North American direct-mail supplement ...
Cached Medicine News:Health News:XIRING and SCM Microsystems Jointly Develop Mobile Terminals for German eHealth Market 2Health News:XIRING and SCM Microsystems Jointly Develop Mobile Terminals for German eHealth Market 3Health News:Ohio's Regulation of RU-486 Clear and Constitutional, Should Be Upheld Argues AUL in Brief Filed Before Ohio Supreme Court 2Health News:A Mindful Chocolate Meditation 2Health News:Donations, Education, and People-Power Mark MassMutual Breast Cancer Awareness Month Efforts 2Health News:Donations, Education, and People-Power Mark MassMutual Breast Cancer Awareness Month Efforts 3Health News:Donations, Education, and People-Power Mark MassMutual Breast Cancer Awareness Month Efforts 4Health News:Perth Leadership Institute Issues Alert on the Post-Crash Environment Facing HR/Leadership Development 2Health News:Perth Leadership Institute Issues Alert on the Post-Crash Environment Facing HR/Leadership Development 3Health News:Dr. Lark Creates Nutritional Supplement to Restore Thick Hair and Strong Nails 2Health News:Dr. Lark Creates Nutritional Supplement to Restore Thick Hair and Strong Nails 3
... an innovative, quick and easy automated ... 60% less space on your laboratory ... this amazingly easy-to-use, one-hand system, you ... whole range of Diamond Tips. All ...
200 L, Racked, Pre-sterilized, 96 tips/rack, clear Recommended for 20, 25, 50, 100 and 200 L pipettes. Can also be used with 300 L pipettes when pipetting 200 L or less....
MBP's equivalent to the "Universal Yellow" tip, this 200 L tip utilizes a MicroPoint design for accurate sample handling. 10 L Ref. mark....
For the quantitative determination of luteinizing hormone (LH) concentration in human serum....
Medicine Products: